|
1
|
von Rossum A, Laher I and Choy JC:
Immune-mediated vascular injury and dysfunction in transplant
arteriosclerosis. Front Immunol. 5:6842014.PubMed/NCBI
|
|
2
|
Rahmani M, Cruz RP, Granville DJ and
McManus BM: Allograft vasculopathy versus atherosclerosis. Circ
Res. 99:801–815. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Visse R and Nagase H: Matrix
metalloproteinases and tissue inhibitors of metalloproteinases:
Structure, function, and biochemistry. Circ Res. 92:827–839. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Galis ZS and Khatri JJ: Matrix
metalloproteinases in vascular remodeling and atherogenesis: The
good, the bad, and the ugly. Circ Res. 90:251–262. 2002.PubMed/NCBI
|
|
5
|
Sommer W, Knöfel AK, Izykowski N, Oldhafer
F, Avsar M, Jonigk D, Warnecke G and Haverich A: Physical exercise
reduces transplant arteriosclerosis in a mouse aorta
transplantation model. J Thorac Cardiovasc Surg. 149:330–337. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mitchell RN: Learning from rejection: What
transplantation teaches us about (other) vascular pathologies. J
Autoimmun. 45:80–89. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dimas G, Iliadis F and Grekas D: Matrix
metalloproteinases, atherosclerosis, proteinuria and kidney
disease: Linkage-based approaches. Hippokratia. 17:292–297.
2013.PubMed/NCBI
|
|
8
|
Kitamura H, Ohno Y, Toyoshima Y, Ohtake J,
Homma S, Kawamura H, Takahashi N and Taketomi A:
Interleukin-6/STAT3 signaling as a promising target to improve the
efficacy of cancer immunotherapy. Cancer Sci. 108:1947–1952. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Calautti E, Avalle L and Poli V:
Psoriasis: A STAT3-centric view. Int J Mol Sci. 19:pii: E171.
2018.PubMed/NCBI
|
|
10
|
Solomon A, Li DQ, Lee SB and Tseng SC:
Regulation of collagenase, stromelysin, and urokinase-type
plasminogen activator in primary pterygium body fibroblasts by
inflammatory cytokines. Invest Ophthalmol Vis Sci. 41:2154–2163.
2000.PubMed/NCBI
|
|
11
|
Lakatta EG: The reality of aging viewed
from the arterial wall. Artery Res. 7:73–80. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Struewing IT, Durham SN, Barnett CD and
Mao CD: Enhanced endothelial cell senescence by lithium-induced
matrix metalloproteinase-1 expression. J Biol Chem.
284:17595–17606. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu WB and Huang TF: Activation of MMP-2,
cleavage of matrix proteins and adherens junctions during a snake
venom metalloproteinase-induced endothelial cell apoptosis. Exp
Cell Res. 288:143–157. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shapiro S, Khodalev O, Bitterman H,
Auslender R and Lahat N: Different activation forms of MMP-2
oppositely affect the fate of endothelial cells. Am J Physiol Cell
Physiol. 298:C942–C951. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xiao Q, Zhang F, Grassia G, Hu Y, Zhang Z,
Xing Q, Yin X, Maddaluno M, Drung B, Schmidt B, et al: Matrix
metalloproteinase-8 promotes vascular smooth muscle cell
proliferation and neointima formation. Arterioscler Thromb Vasc
Biol. 34:90–98. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Austin KM, Nguyen N, Javid G, Covic L and
Kuliopulos A: Noncanonical matrix
metalloprotease-1-protease-activated receptor-1 signaling triggers
vascular smooth muscle cell dedifferentiation and arterial
stenosis. J Biol Chem. 288:23105–23115. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hsieh JL, Shiau AL, Lee CH, Yang SJ, Lee
BO, Jou IM, Wu CL, Chen SH and Shen PC: CD8+ T
cell-induced expression of tissue inhibitor of metalloproteinses-1
exacerbated osteoarthritis. Int J Mol Sci. 14:19951–19970. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Raffetto JD and Khalil RA: Matrix
metalloproteinases and their inhibitors in vascular remodeling and
vascular disease. Biochem Pharmacol. 75:346–359. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ries C: Cytokine functions of TIMP-1. Cell
Mol Life Sci. 71:659–672. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lambert E, Dassé E, Haye B and Petitfrère
E: TIMPs as multifacial proteins. Crit Rev Oncol Hematol.
49:187–198. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kashiwagi M, Tortorella M, Nagase H and
Brew K: TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4)
and aggrecanase 2 (ADAM-TS5). J Biol Chem. 276:12501–12514. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hubmacher D and Apte SS: ADAMTS proteins
as modulators of microfibril formation and function. Matrix Biol.
47:34–43. 2015. View Article : Google Scholar : PubMed/NCBI
|
